Speaker Profile

Senior Vice President, Public Policy and External Affairs, Thrive Earlier Detection

Biography
Prior to joining Thrive, she was vice president, head of public policy for Foundation Medicine, where she was responsible for developing, advocating and executing company positions before Congress and the U.S. Food and Drug Administration (FDA), including the landmark parallel review decision by the FDA and Centers for Medicare and Medicaid Services (CMS) on next generation sequencing for Foundation Medicine’s flagship product. Before that, she spent time outside of the industry, as senior counsel to Senator Arlen Specter, where she was lead policy and strategic advisor for issues related to tax, banking, healthcare and finance. Prior to that, she was lead counsel to the Senate Judiciary Committee, providing policy analysis and strategic counsel to both Chairman Specter and Republican and Democrat senators on the Committee.


 Session Abstract – PMWC 2022 Silicon Valley


The analysis of blood for circulating tumor cells (CTC), circulating tumor DNA (ctDNA), extracellular vesicles, or more recently, tumor-educated platelets has opened new avenues for cancer diagnostics, including early detection of tumors, improved risk assessment and staging, as well as early detection of relapse to improve patient care. The track will introduce the up-to-date technologies used in liquid biopsy and review the clinical utilities in cancer screening, detection of minimal residual diseases, selection of molecular-targeted drugs, as well as monitoring of treatment responsiveness.

Sessions:

  • Early Cancer Detection- Status quo, Technical and Clinical Challenges, and the Future (PANEL)
    Session Chair: Jimmy Lin, Freenome
    - Nicholas Dracopoli, delfi Diagnostics
    - Ash Alizadeh, Stanford
    - Amir Ali Talasaz, Guardant Health
    - Matt Franklin, Exact Sciences
  • How is Liquid Biopsy Changing the Testing Paradigm for Oncology Patients? (PANEL)
    Session Chair: Rebecca Brandes, Agilent
    - Kenna Anderes, Mirati
    - Kate Knobil, Agilent
  • The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
    - Alexey Aleshin, Natera
  • Liquid Biopsy for Screening, Diagnosis, Prognosis and Therapy Guidance
    Session Chair: Sam Salman, miR Scientific
    - Matt Franklin, Exact Sciences
  • The Advantages of Exosomes as a Liquid Biopsy Based Markers
    Session Chair: Johan Skog, Exosome Diagnostics
    - Jamil Azzi, Harvard
    - Dolores Di Vizio, Cedars-Sinai Medical Center
  • The Current Regulatory Landscape of Liquid Biopsy In Oncology
    Session Chair: Deepshikha Bhandari, Grail Bio
    - Seema Singh Bhan, Exact Sciences
    - Ryan Woodhouse, Foundation Medicine
  • Showcase
    - Samuel Levy, Bluestar Genomics
    - Richard Chen, Personalis